Aug 7 (Reuters) - CureVac ( CVAC ) said on Thursday that

the company and GSK have entered an agreement to a

resolve patent dispute with Pfizer ( PFE ) and BioNTech

related to mRNA-based COVID-19 vaccines.

As part of the settlement, CureVac ( CVAC ) and GSK will receive a

combined payment of $740 million and single-digit royalties on

sales of COVID-19 vaccines in the U.S. going forward.

CureVac ( CVAC ) will also grant BioNTech and Pfizer ( PFE ) a non-exclusive

license to manufacture, use, import and sell mRNA-based COVID-19

and influenza products in the U.S.